Quick summary
Cerebrolysin is a neuropeptide mixture derived from porcine brain tissue, approved in over 40 countries for stroke recovery, TBI, and dementia. It mimics endogenous neurotrophic factors (BDNF, GDNF, NGF) and has over 200 clinical trials and 1,000+ publications.
Overview
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through controlled enzymatic proteolysis. It has been approved in over 40 countries (notably in Europe, Russia, China, and South Korea) for stroke recovery, traumatic brain injury, and dementia. It is one of the most clinically studied neurotrophic treatments, with over 200 clinical trials and 1,000+ publications.
Mechanism of action
Cerebrolysin mimics the action of endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF). Its peptide fragments cross the blood-brain barrier and activate multiple neuroprotective and neuroregenerative pathways: inhibiting calpain-mediated neuronal death, reducing amyloid-beta aggregation (relevant to Alzheimer's), promoting neurogenesis and synaptogenesis, modulating GSK-3β activity, and reducing neuroinflammation. It acts on the PI3K/Akt survival pathway and inhibits apoptosis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| cognitive enhancement / neuroprotection | intramuscular | 5–10 mL | daily | Standard protocol: 5-10mL IM daily for 10-20 days. Stroke protocols use higher IV doses (30-50mL). Repeat courses every 3-6 months. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The CASTA trial (1,070 patients) showed improved neurological outcomes in acute ischemic stroke. Meta-analyses of Alzheimer's trials show consistent improvements in cognitive function (ADAS-cog scores). Studies in traumatic brain injury demonstrate faster recovery and better functional outcomes. A Cochrane review noted the evidence for stroke is 'promising but not conclusive' and called for more standardized trials. Used extensively in post-Soviet and Asian clinical practice with decades of real-world safety data. Not studied in large-scale Western trials.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Cerebrolysin for synergistic effects.
Legal status
Approved as a prescription drug in 40+ countries. Not FDA-approved. Classified as a biological product. Available through international pharmacies.
Sourcing & access
Prescription required
Cerebrolysin is an FDA-approved prescription medication available through licensed healthcare providers, telehealth platforms, and 503A/503B compounding pharmacies.
Frequently asked questions
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. It is approved in over 40 countries for stroke recovery, traumatic brain injury, and dementia, making it one of the most studied neurotrophic treatments available.
Cerebrolysin is not FDA-approved but is approved as a prescription drug in over 40 countries including across Europe, Russia, China, and South Korea. It is classified as a biological product and is available through international pharmacies.
Meta-analyses of Alzheimer's trials show consistent improvements in cognitive function as measured by ADAS-cog scores. It reduces amyloid-beta aggregation and promotes neurogenesis and synaptogenesis, though a Cochrane review has called for more standardized trials.
The standard protocol is 5 to 10 mL intramuscularly daily for 10 to 20 days, repeated every 3 to 6 months. Stroke protocols use higher intravenous doses of 30 to 50 mL.
Side effects include dizziness, headache, injection site pain, and rarely agitation, insomnia, or nausea. Decades of clinical use across Europe, Russia, China, and South Korea, backed by over 200 clinical trials and more than 1,000 publications, have established a generally favorable safety profile in adult neurological indications.
Research references
- Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trialsPubMed
- Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezilPubMed
- Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled TrialsPubMed
- Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trialsPubMed
- Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trialPubMed